Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02886065
Title A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.